Globally, death due to cancers is likely to rise to over 20 million by 2030, which has created an urgent need for novel approaches to anticancer therapies such as the development of host defence peptides. Cn-AMP2 (TESYFVFSVGM), an anionic host defence peptide from green coconut water of the plant, Cocos nucifera, and showed anti-proliferative activity against the 1321N1 and U87MG human glioma cell lines with IC50 values of 1.25 and 1.85 mM respectively. The membrane interactive form of the peptide was found to be an extended conformation, which primarily included β-type structures (levels > 45%) and random coil architecture (levels > 45%). Based on these and other data, it is suggested that the short anionic N-terminal sequence (TES) of Cn-AMP2 interacts with positively charged moieties in the cancer cell membrane. Concomitantly, the long hydrophobic C-terminal sequence (YFVFSVGM) of the peptide penetrates the membrane core region, thereby driving the translocation of Cn-AMP2 across the cancer cell membrane to attack intracellular targets and induce anti-proliferative mechanisms. This work is the first to demonstrate that AHDPs have activity against human glioblastoma, which potentially provides an untapped source of lead compounds for development as novel agents in the treatment of these and other cancers.
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Introduction
Globally, cancer is now one of the leading causes of death which claimed lives at an annual rate of over 12.7 million in 2008 and is predicted to rise to over 20 million by 2030, [1] , which has created an urgent need for novel approaches to anticancer therapies [2] [3] [4] . In response, there has been a move to develop anticancer strategies that are based on compounds from natural sources [5] [6] [7] [8] , including host defence peptides (HDPs) [9] [10] [11] . These peptides are multi-functional components of innate immune systems across the eukaryotic kingdom [12, 13] that show a potent ability to kill a wide variety of cancer cells [9, 11] and microbes [12, 14] . The vast majority of HDPs are cationic (CHDPs) [15, 16] , which underpins their ability to discriminate against the membranes of healthy mammalian cells, which possess no overall charge, and target the membranes of microbial and cancer cell, which possess a net anionic charge [9, 11, 12, 14] . Numerous studies have shown that membrane interaction is fundamental to the antimicrobial and anticancer activity of CHDPs and that in both cases, these interactions involve generally similar mechanisms [17] . In some instances, these mechanisms involve the translocation of these peptides across the plasma membranes of target cells to attack intracellular targets such as bacterial DNA [18, 19] or cancer cell mitochondria [20, 21] .
However, most usually, the antimicrobial and anticancer mechanisms used by CHDPs involve direct attack on the membranes of target cells themselves, which can lead to death of the host cell via a variety of membranolytic processes that involve lipid perturbation and permeabilisation of the bilayer. [9, 11, 12, 14] . A number of major models have been proposed to describe these processes such as the carpet mechanism and the toroidal pore model [17] with more recent examples, including; the tilted peptide mechanism [22] and amyloid-mediated mechanisms [23] .
It is generally believed that the relatively non-specific nature of the processes involved in the antimicrobial and anticancer action of CHDPs renders it unlikely that resistance to this action can be acquired by microbes [12, 14] and cancer cells [9, 11] . In the fight against rising global levels of cancer [24] and microbial infections [25, 26] , this gives CHDPs a major advantage over conventional antibiotics and anticancer compounds, which show declining efficacy largely due to the increasing occurrence of multi-drug resistance in both microbial [27] and cancer cells [28] . In response, the therapeutic potential of CHDPs has been intensively investigated with the result that a number of these peptides are either in late-stage clinical trials or medical use as antimicrobial agents [29, 30] whilst most recently, the neutraceutical protein, lactoferrin, was patented as an anticancer agent [31] and in clinical trials, was shown to reduce the risk of colon carcinogenesis [32] . It has been predicted that many more CHDPs will soon advance to the stage of clinical trials as anticancer agents in the light of recent research progress [20, 21] . Nonetheless, in addition to CHDPs, anionic HDPs (AHDPs) have been increasingly recognised as an integral and important part of the innate immune system and thereby as a potential source of antimicrobial agents with novel mechanisms of action [33, 34] . There have been very few studies on the anticancer activity of AHDPs [35] and here, we have investigated the anticancer ability of Cn-AMP2 (TESYFVFSVGM), which is an AHDP from green coconut water with broad range antibacterial activity [36] , against the human glioma cell lines, 1321N1
and U87MG.
Materials and Methods

Reagents
Cn-AMP2 [36] was supplied by Pepceuticals (UK), produced by solid phase synthesis and purified by HPLC to greater than 99%, which was confirmed by MALDI mass spectrometry.
The peptide was stored as a stock solution of 3 mM in dimethylsulphoxide (DMSO; 2% v/v) at -20°C. All phospholipids were supplied by Avanti Polar Lipids (USA). SVGp12, a noncancerous foetal glial cell line, along with the human glioma cell lines 1321N1 (grade II) and U87MG (grade IV) were obtained from the European Collection of Cell Cultures, UK.
Cisplatin was purchased from Sigma-Aldrich (UK).
Growth conditions for cancer cell lines
The foetal bovine serum (FBS) and 2 mM L-glutamine (Lonza, UK). Each of these cell lines was maintained in a 37 ºC humidified incubator supplied with 5% CO2, all as previously described [37] . respectively, all as previously described [37] . The following day when the cells were circa Figure 1 shows the effect of Cn-AMP2 on the viability of cell lines when incubated as described above. Increasing concentrations of the peptide led to progressively larger reductions in the viability the human glioma cell lines, 1321N1 and U87MG, until at a Cn-AMP2 concentration 2.0 mM, these reductions were circa 70% as compared to controls. In contrast, at the same peptide concentration, Cn-AMP2 induced reductions in the viability of the non-cancerous, human glial cell-line, SVGp12, of circa 25% as compared to controls. Cell viability was determined by the MTS assay as described above and each data entry was the mean of 4 repeats and the error bars represent ± the standard deviation. Regression analysis of these data entries yielded IC50 values for Cn-AMP2 that were 1.25 mM for the 1321N1 cell line and 1.85 mM for U87MG cell line.
Sequence analysis and molecular modelling of Cn-AMP2
The primary structure of Cn-AMP2, TESYFVFSVGM, was obtained from [36] and the potential of the peptide to adopt membrane interactive α-helical structure determined by hydrophobic moment plot analysis. This methodology uses the mean hydrophobic moment, < µH >, to measure the structured partitioning of hydrophobic and hydrophilic amino acid residues in a regular repeat structure [39, 40] . Molecular dynamic (MD) simulations to model the interactions of Cn-AMP2 with a DMPC:DMPS (10:1) bilayer were undertaken. The peptide was assembled using the AMBER tools 1.5 program [41] and minimized using the GROMOS53a6 force field (2,3), which was equilibrated at room temperature in water. All simulations were performed with GROMACS software package [42, 43] . The force field for DMPS and DMPC was based on the GROMOS53a6 force fields with minor modification taken from the literature [44] . All structures were equilibrated at room temperature in water (NVT and NPT simulations) and bilayers contained 128 lipids in a box, which was 6.53 nm x 6.53 nm x 10.0 nm parallel to the z-axis. The GROMOS96 force field step descendent method was utilised to minimise the structure and, employing a 400 ns equilibration run at 310 K, simulations were performed using the NPT ensemble. The Cn-AMP2 molecule was inserted into the box containing the solvated bilayer and an equilibration run was carried out for the system. The stability of association of the peptide with the surface of the DMPC:DMPS (10:1)
bilayer was estimated by determining the energy required to induce Cn-AMP2 to occupy a location in the membrane interior, which was performed using the potential of mean force (PMF) facility available in Gromacs [45] . The potential energy of the system was extracted for slower pulling simulations with a pulling rate of 0.1 Å/ns for 40 ns and Cn-AMP2 was pulled in the direction parallel to the Z axis (5).
9 The preparation of SUVs Small unilamellar vesicles (SUVs) were constructed with a mean diameter of 0.1 μM all as previously described [46] . Essentially, either pure lipids or lipid mixtures were dissolved in chloroform (5 mg ml -1 ), dried under N2 and further dried under vacuum overnight. The resulting lipid film was rehydrated using phosphate buffered saline [PBS; pH 7.5] containing NaCl (150 mM) and sonicated for an hour or until the solution was no longer turbid. To form SUVs, these solutions were then freeze-thawed (× 5) and extruded (× 11) using an Avanti polar lipid mini-extruder apparatus containing a 0.1 µm polycarbonate filter (Avanti, USA).
CD structural analyses of Cn-AMP2
Cn-AMP2 (0.1 mg ml -1 ) was dissolved in either phosphate buffered saline [PBS; pH 7.5] or 50% (v/v) trifluorethanol (TFE). The peptide was also dissolved in suspensions of SUVs, of either DMPC, DMPS or DMPC / DMPS (10:1), all prepared as described above, to
give a peptide to lipid molar ratio of 1:100. All samples were analyzed at 20 °C on a J-815 spectropolarimeter (Jasco, UK) over a wavelength range of 260 to 180 nm, using a band width of 1 nm and a scan speed of 100 nm min -1 . For all spectra produced, the baseline acquired in the absence of Cn-AMP2 was subtracted and levels of secondary structure in the peptide estimated using Dichroweb [47] [48] [49] .
The membranolytic ability of Cn-AMP2
Calcein release assay: SUVs were prepared from either DMPC, DMPS or DMPC / DMPS (10:1) all as described above except that lipid (7.5 mg) was dissolved in chloroform. After drying, the resulting lipid film was hydrated with 1 ml of HEPES (5 mM; pH 7.5) containing calcein (70 mM). SUVs with entrapped calcein were separated from free calcein by gel filtration using HEPES (5 mM; pH 7.5) as an elutant and a Sephadex G75 column (SIGMA), which was hydrated over-night with HEPES (20mM; pH 7.4) containing NaCl (150 mM) and EDTA (1.0 mM). The ability of Cn-AMP2 to lyse these SUVs was determined by assaying calcein release. Essentially, aliquots (20 µl) of solutions containing SUVs with entrapped calcein and Cn-AMP2 at final concentrations in the range 0 µM to 400 µM were incubated with 2 ml of HEPES (20 mM; pH 7.4) containing NaCl (150 mM) and EDTA (1.0 mM). The fluorescence intensity of released calcein was measured using a FP-6500 spectrofluorometer (JASCO, Tokyo Japan) with an excitation wavelength of 490 nm and an emission wavelength of 520 nm. The change in fluorescence observed for calcein release when SUVs were dissolved in Triton-X100 (20 µl) was taken to represent 100% lysis and used to determine the percentage lysis of these SUVs by Cn-AMP2.
Haemolysis assay:
The haemolytic activity of Cn-AMP2 was investigated using a standard assay [50, 51] . Essentially, fresh human red blood cells (3 ml) were washed 3 times with phosphate buffered saline (PBS, pH 7.4) by centrifugation for 5 minutes at 1200 × g until the supernatant was clear. Washed red blood cells were resuspended in PBS to a final volume of 20 ml. Peptide solutions (10 µl) were added to 190 µl suspension of washed red blood cells and were incubated for 1h at 37 °C. The samples were then centrifuged at 12000 × g for 5 minutes. The release of haemoglobin was monitored by diluting 100 µl of supernatant with 900 µl PBS and measuring the absorbance at 576 nm. For negative and positive controls, PBS buffer and 0.1% Triton X-100 were used.
Results and discussion
There is an urgent need for new anticancer agents with novel mechanisms of action and it has been predicted that AHDPs may be an untapped source of such agents [33, 34] . Plants are known to be prolific producers of novel anticancer compounds [7, 52, 53] and the biggest single source of AHDPs with anticancer activity [35] . Accordingly, here, we have investigated the ability of Cn-AMP2, which is an AHDP found in green coconut water, derived from Cocos nucifera of the Arecaceae [36] , to inactivate the human glioma cell lines, 1321N1 and U87M.
It was found that increasing concentrations of Cn-AMP2, led to progressively larger reductions in the viability of cell lines until at a peptide concentration 2.0 mM, these reductions were circa 70% ( Figure 1 ). In contrast, across the same concentration range, the peptide induced reductions in the viability of the non-cancerous, glial cell-line, SVGp12, of circa 25% ( Figure   1 ). Regression analysis of these data yielded IC50 values for Cn-AMP2 that were 1.25 mM for the 1321N1 cell line and 1.85 mM for the U87MG cell line as compared to untreated controls.
In combination, these results show that Cn-AMP2 has selective toxicity for cancer cells and comparable results were recently reported for the anticancer activity of Cr-ACP1, which is an AHDP that was recently isolated from Cycas revolute, a plant of the Cycadaceae family [54] . Figure 3 shows CD spectra of Cn-AMP2 in aqueous solution (black), in TFE (dotted black), which is an α-helix promoting solvent, and in the presence of small unilamellar vesicles (SUVs), which were formed from a range of membrane lipids. These SUVs include those formed from: DMPC (grey) and DMPS (light grey) respectively, which are the major anionic and zwitterionic lipids in cancer cell membranes, and DMPC / DMPS (10:1) (dotted grey), which can be taken as representative of cancer cell membranes . Levels of secondary structure possessed by the peptide were determined from these spectra and in all cases examined, Cn-AMP2 showed no significant propensity to adopt α-helical structure (levels < 10%) but rather occurred in an extended conformation, which primarily included β-type structures (levels > 45%) and random coil architecture (levels > 45%).
The anticancer activity of all known HDPs involves interaction with the plasma membrane of these cells, leading to cell death via either membranolytic mechanisms or translocation of the peptide to attack intracellular targets [9] . Cell cultures of 1321N1 and U87MG that had been treated with Cn-AMP2 up to a concentration of 2.0 mM showed no evidence of staining in the presence of Trypan blue, strongly suggesting that the anticancer action of the peptide does not involve membranolytic mechanisms. Reinforcing this suggestion, microscopic examination of these cultures showed that cells treated with Cn-AMP2 exhibited no significant differences in morphology to that of control cells; no evidence of celldeath, as indicated by a round morphology; and no sign of cell lysis, as witnessed by membrane fragmentation or the presence of cellular debris (Figure 2 ). In combination, these data suggest 14 that Cn-AMP2 may be cytostatic, exerting its activity against the 1321N1 and U87MG cell lines by entering these cells and inhibiting their ability to proliferate. The anti-proliferative mechanism of the peptide was not further investigated but one possibility may be that Cn-AMP2 induces apoptotic cell death pathways via DNA-binding as was proposed for Cr-ACP1, which is also a mono-anionic peptide that shows anti-proliferative activity [54] .
A clear implication from these anticancer studies is that Cn-AMP2 has the ability to translocate cancer cell membranes and it has previously been predicted that the peptide may interact with membranes via the formation of amphiphilic α-helical structure [36] . Many HDPs adopt this structure to facilitate partitioning into target membranes, which is reflected by their generally high values of <µH >, a well-established measure of amphiphilicity [39, 40] .
However, sequence analysis of Cn-AMP2 predicted that the peptide had only a very low potential to adopt α-helical structure with a mean hydrophobic moment of <µH > == 0.044, which was were confirmed by CD structural analysis of the peptide. This analysis showed that
Cn-AMP2 exhibited no significant propensity to adopt this form of secondary structure under any of the experimental conditions investigated (Table 2 ; Figure 3 ), particularly in the presence of SUVs formed from DMPC / DMPS (10:1), which are generally taken to mimic cancer cell membranes [55] . Rather, in the presence of these SUVs and all other cases examined, the secondary structure of Cn-AMP2 was primarily formed from β-type structures (levels > 45%) and random coil architecture (> 45%) ( Table 2 ; Figure 3 ), suggesting that an extended conformation was the membrane interactive form of the peptide. Visual examination of the primary structure of Cn-AMP2 [36] shows that in an extended form, the C-terminal eight residues of the peptide, YFVFSVGM, form a strongly hydrophobic region, which is flanked by a short anionic segment, TES. This residue arrangement endows Cn-AMP2 with primary amphiphilicity, which has been reported for other anticancer peptides such as indolicidin [56] and is known to mediate the ability of these peptides to traverse membranes [9, 57] . Figure 4 shows molecular dynamic simulations for the interaction of Cn-AMP2 with a DMPC / DMPS (10:1) bilayer, which is a lipid composition generally taken to model cancer cell membranes [55] . In an extended conformation, Cn-AMP2 approaches the membrane surface ( Figure 4A ) and inserts ( Figure 4B ). Insertion of the peptide involves association of its anionic N-terminal segment (TES) with positively charged moieties in the head-group region of the bilayer such as the choline group of DMPC. Complementing these electrostatic interactions, the hydrophobic C-terminal segment of Cn-AMP2 (YFVFSVGM) penetrates the apolar core region of the membrane ( Figure 4B ). Led by its N-terminal region, the peptide then traverses this core region ( Figure 4C ) and emerges through the opposing leaflet to migrate away from the membrane surface ( Figure 4D ) with no significant overall perturbation of the bilayer resulting from the passage of Cn-AMP2 (Figures A to D) . Based on the action of the peptide against the human glioma cell lines, 1321N1 and U87MG, it is likely that emergent Cn-AMP2 attacks intracellular targets with the result that the ability of these cells to proliferate is inhibited ( Figure 4E ).
16
The ability of Cn-AMP2 was to lyse human erythrocytes and dye-filled vesicles with lipid compositions mimetic of cancer cell membranes was investigated and no evidence of either haemoglobin or calcein release was detected, indicating that the peptide had no detectable membranolytic ability. These results are consistent with the action of the peptide on 1321N1 and U87MG cell lines and strongly support the suggestion that Cn-AMP2 may translocate cancer cell membranes to attack intracellular targets. To investigate potential mechanisms by which the peptide may translocate these membranes, molecular dynamic simulations were undertaken (Figure 4 ). These simulations predicted that translocation of a DMPC / DMPS (10:1) bilayer by Cn-AMP2 would involve a mechanism, which was based on the primary amphiphilicity of the peptide. As can be seen from figure 4, in an extended conformation, Cn-AMP2 approaches the membrane surface ( Figure 4A ) and inserts ( Figure   4B ). Insertion of the peptide involves association of its anionic N-terminal segment (TES) with positively charged moieties in the head-group region of the bilayer such as the choline group of DMPC. Complementing these electrostatic interactions, the hydrophobic C-terminal segment of Cn-AMP2 (YFVFSVGM) penetrates the apolar core region of the membrane ( Figure 4B ). Led by its N-terminal region, the peptide then traverses this core region ( Figure   4C ) and emerges through the opposing leaflet to migrate away from the membrane surface ( Figure 4D ) with no significant overall perturbation of the bilayer resulting from the passage of Cn-AMP2 (Figures A to D) . Based on the action of the peptide against the human glioma cell lines, 1321N1 and U87MG, it is likely that emergent Cn-AMP2 then attacks intracellular targets such as DNA with the result that the ability of these cells to proliferate is inhibited ( Figure 4E ).
In summary, this study has shown that Cn-AMP2 has activity against several human glioma, expanding the small repertoire of AHDPs known to possess anticancer activity [33, 34] . The action of Cn-AMP2 against these cancer cells appears to involve anti-proliferative mechanisms, which result from the ability of the peptide to translocate cancer cell membranes through a hydrophobicity-driven mechanism. Use of this mechanism would seem to reflect the fact that Cn-AMP2 is devoid of cationic residues and therefore lacks the capacity to engage in the electrostatically-driven mechanisms of cancer cell targeting utilised by most HDPs [9] .
However, this lack of cationic residues could also give Cn-AMP2 an advantage over CHDPs with anticancer action whose possession of lysine and arginine residues makes them highly susceptible to degradation by human proteases [20, 58] . Clearly, the levels of Cn-AMP2 shown here to be necessary for anticancer activity are prohibitive for the therapeutic application of the peptide. However, given the problems due to the increasing prevalence of cancer on a global scale and the urgent need for solutions, we suggest that Cn-AMP2 may represent a template for the development of novel HDPs with clinically useful, anticancer activity.
